Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
Subscribe To Our Newsletter & Stay Updated